3 thoughts on “EU FMD: Aggregation Is Not Mandated, But It Will Be Necessary”
Comments are closed.
Comments are closed.
DISCLAIMER: RxTrace contains some of the personal thoughts, ideas and opinions of Dirk Rodgers. The material contained in RxTrace is not legal advice. Dirk Rodgers is not a lawyer.
The reader must make their own decisions about the accuracy of the opinions expressed in RxTrace. Readers are encouraged to consult their own legal counsel
and trading partners before taking any actions based on information found in RxTrace. RxTrace is not a vehicle for communicating
the positions of any company, organization or individual other than Dirk Rodgers.
RxTrace, a comprehensive exploration of the intersection between healthcare supply chains, track and trace technology, standards and global regulatory compliance.
Contact Us | Privacy Statement
Copyright © 2009-2017 Dirk Rodgers Consulting, LLC. All Rights Reserved.
RxTrace is a registered trademark of Dirk Rodgers Consulting, LLC
L, A, S, C
The conclusion is obvious from reading the FMD. There is not a simple things like POD as the entire security of the system relies of the ability to decommissioned the serial numbers. If we want to avoid aggregation, then we need to study additional measure that are definitely not included in the regulation where the serialization information is combined with anti counterfeiting solutions.
Hi, Dirk! Thanks for putting together all my concerns regarding the EU FMD. I cannot stop hoping that EMVO will finally realize this deficiency and do further improvements on the EU-Hub to create the ability of receiving aggregation data.
Well said. Thanks for analysis. Just one minor correction: Norway and Switzerland are part of EU FMD covered area, Norway due to EEA and Switzerland due to opt-in (which was requested by the local industry).